SCHEMBL4476435

SCHEMBL4476435

C#Cc1ncc(-c2ccc(Cl)cc2)cc1CN

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 9/20 0.40
CYP1A2 P05177 3/20 0.37
KCNH2 Q12809 1/20 0.37
MINK1 Q8N4C8 1/20 0.37
TNIK Q9UKE5 1/20 0.37
NOTUM Q6P988 2/20 0.36
LTA4H P09960 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2C19 P33261 2/20 0.35
CYP3A4 P08684 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP2C9 P11712 1/20 0.35
EGLN1 Q9GZT9 1/20 0.34
INPPL1 O15357 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493198 0.80 MAP4K4 (0.37) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL4486915 0.80 PIK3CD (0.47) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL4481669 0.79 AHR (0.44) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL2324233 0.76 CHRM1 (0.42) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL4490469 0.76 MAP4K4 (0.43) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL4482838 0.76 MAP4K4 (0.40) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL4493973 0.73 MAP4K4 (0.37) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL10017415 0.70 MAP4K4 (0.54) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL2322615 0.66 LTA4H (0.43) MAP4K4CYP1A2KCNH2MINK1TNIK
SCHEMBL28826036 0.65 TAAR1 (0.43) MAP4K4CYP1A2NOTUMMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592358-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP disclosed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 MAP4K4 2864/4885CYP1A2 3196/4885KCNH2 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.